Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial

医学 安慰剂 内科学 胃肠病学 临床终点 C反应蛋白 纤维蛋白原 随机对照试验 肾脏疾病 随机化 炎症 病理 替代医学
作者
Yukihiro Wada,Camilla Jensen,Anna Sina P. Meyer,Amir Abbas Mohseni Zonoozi,Hirokazu Honda
出处
期刊:Journal of Cardiology [Elsevier BV]
卷期号:82 (4): 279-285 被引量:17
标识
DOI:10.1016/j.jjcc.2023.05.006
摘要

Despite optimal treatment, a residual inflammatory risk often remains in patients with atherosclerotic cardiovascular disease. In a US-based phase 2 trial, ziltivekimab, a fully human monoclonal antibody targeting the interleukin-6 ligand, significantly reduced biomarkers of inflammation compared with placebo in patients at high atherosclerotic risk. Here, we report the efficacy and safety of ziltivekimab in Japanese patients.RESCUE-2 was a randomized, double-blind, 12-week, phase 2 trial. Participants aged ≥20 years with stage 3-5 non-dialysis-dependent chronic kidney disease and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L were randomized to receive placebo (n = 13) or subcutaneous ziltivekimab 15 mg (n = 11) or 30 mg (n = 12) at Weeks 0, 4, and 8. The primary endpoint was percentage change in hsCRP levels from baseline to end of treatment (EOT; mean of Week 10 and Week 12 values).At EOT, median hsCRP levels were reduced by 96.2 % in the 15 mg group (p < 0.0001 versus placebo), by 93.4 % in the 30 mg group (p = 0.002 versus placebo), and by 27.0 % in the placebo group. Serum amyloid A and fibrinogen levels were also reduced significantly. Ziltivekimab was well tolerated and did not affect total cholesterol to high-density lipoprotein cholesterol ratios. There was a small, but statistically significant increase in triglyceride levels with ziltivekimab 15 mg and 30 mg compared with placebo.The efficacy and safety results support the development of ziltivekimab for secondary prevention and the treatment of patients at high atherosclerotic risk.gov identifier, NCT04626505.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
橙子完成签到,获得积分10
刚刚
陈补天完成签到 ,获得积分10
1秒前
CipherSage应助慧灰huihui采纳,获得10
2秒前
乐观健柏完成签到,获得积分10
3秒前
5秒前
CodeCraft应助大橙子采纳,获得10
5秒前
量子星尘发布了新的文献求助10
6秒前
jeeya完成签到,获得积分10
7秒前
9秒前
科目三应助科研通管家采纳,获得10
9秒前
科目三应助科研通管家采纳,获得10
9秒前
伦语发布了新的文献求助10
9秒前
顾矜应助科研通管家采纳,获得10
9秒前
xuzj应助科研通管家采纳,获得10
9秒前
xuzj应助科研通管家采纳,获得10
9秒前
9秒前
NexusExplorer应助科研通管家采纳,获得10
9秒前
9秒前
9秒前
丘比特应助科研通管家采纳,获得10
10秒前
yull完成签到,获得积分10
10秒前
小巧书雪完成签到,获得积分10
13秒前
大大怪将军完成签到,获得积分10
14秒前
哈哈哈完成签到 ,获得积分0
14秒前
小怪完成签到,获得积分10
15秒前
爱吃泡芙完成签到,获得积分10
16秒前
白桃战士完成签到,获得积分10
17秒前
19秒前
qingchenwuhou完成签到 ,获得积分10
19秒前
XXX完成签到,获得积分10
20秒前
锡嘻完成签到 ,获得积分10
20秒前
21秒前
彗星入梦完成签到 ,获得积分10
21秒前
恋恋青葡萄完成签到,获得积分10
21秒前
隐形万言完成签到,获得积分10
23秒前
Time完成签到,获得积分10
23秒前
土木研学僧完成签到,获得积分10
24秒前
yjy完成签到 ,获得积分10
24秒前
A溶大美噶完成签到,获得积分10
24秒前
yar应助萨尔莫斯采纳,获得10
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022